NDAINJECTIONINJECTABLE
Approved
Aug 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 8h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHIROCAINE (levobupivacaine hydrochloride) is a long-acting local anesthetic administered by injection for regional anesthesia and pain management. It is the S-enantiomer of bupivacaine, designed to provide prolonged anesthesia with potentially improved cardiac safety profile. The drug is used across surgical, obstetric, and acute pain management settings.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating defensive strategy and smaller commercial footprint focused on retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CHIROCAINE offers limited career growth opportunity given its LOE-approaching status and zero linked job postings, reflecting organizational de-prioritization. Roles available are primarily defensive and focused on protecting market share, pricing strategy, and managed care negotiations in a commoditized anesthetic market.
Brand ManagerProduct Manager
Worked on CHIROCAINE at Purdue Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.